Literature DB >> 23131208

Is poor research the cause of the declining productivity of the pharmaceutical industry? An industry in need of a paradigm shift.

Frank Sams-Dodd1.   

Abstract

For the past 20 years target-based drug discovery has been the main research paradigm used by the pharmaceutical industry and billions of dollars have been invested into this approach. However, recent industry data strongly indicate that the target-based approach is not an effective drug discovery paradigm and is likely to be the cause of the productivity crisis the industry is experiencing. However, from a theoretical and scientific perspective the target-based approach appears sound, so why is it not more successful? The purpose of this paper is first to analyse the real-life implementation of the target-based approach to identify possible reasons for the high failure rate and second to suggest changes to the drug discovery approach, which can improve productivity.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Mesh:

Year:  2012        PMID: 23131208     DOI: 10.1016/j.drudis.2012.10.010

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  24 in total

1.  Pain: novel analgesics from traditional Chinese medicines.

Authors:  Susan L Ingram
Journal:  Curr Biol       Date:  2014-02-03       Impact factor: 10.834

Review 2.  The discovery of first-in-class drugs: origins and evolution.

Authors:  Jörg Eder; Richard Sedrani; Christian Wiesmann
Journal:  Nat Rev Drug Discov       Date:  2014-07-18       Impact factor: 84.694

Review 3.  Phenotypic screening in cancer drug discovery - past, present and future.

Authors:  John G Moffat; Joachim Rudolph; David Bailey
Journal:  Nat Rev Drug Discov       Date:  2014-07-18       Impact factor: 84.694

Review 4.  Small molecule screening in human induced pluripotent stem cell-derived terminal cell types.

Authors:  Sandra J Engle; Fabien Vincent
Journal:  J Biol Chem       Date:  2013-12-20       Impact factor: 5.157

5.  High Throughput Screening for Colorectal Cancer Specific Compounds.

Authors:  Jingping Xie; Chunxia Wang; John C Gore
Journal:  Comb Chem High Throughput Screen       Date:  2016       Impact factor: 1.339

6.  The clinical liver safety assessment best practices workshop: rationale, goals, accomplishments and the future.

Authors:  Paul B Watkins; Michael Merz; Mark I Avigan; Neil Kaplowitz; Arie Regev; John R Senior
Journal:  Drug Saf       Date:  2014-11       Impact factor: 5.606

7.  Large-scale phenotypic drug screen identifies neuroprotectants in zebrafish and mouse models of retinitis pigmentosa.

Authors:  Liyun Zhang; Conan Chen; Jie Fu; Brendan Lilley; Cynthia Berlinicke; Baranda Hansen; Ding Ding; Guohua Wang; Tao Wang; Daniel Shou; Ying Ye; Timothy Mulligan; Kevin Emmerich; Meera T Saxena; Kelsi R Hall; Abigail V Sharrock; Carlene Brandon; Hyejin Park; Tae-In Kam; Valina L Dawson; Ted M Dawson; Joong Sup Shim; Justin Hanes; Hongkai Ji; Jun O Liu; Jiang Qian; David F Ackerley; Baerbel Rohrer; Donald J Zack; Jeff S Mumm
Journal:  Elife       Date:  2021-06-29       Impact factor: 8.140

Review 8.  Metabolomics and systems pharmacology: why and how to model the human metabolic network for drug discovery.

Authors:  Douglas B Kell; Royston Goodacre
Journal:  Drug Discov Today       Date:  2013-07-26       Impact factor: 7.851

9.  An exploratory evaluation of tyrosine hydroxylase inhibition in planaria as a model for parkinsonism.

Authors:  David Prokai; Thinh Nguyen; Kurt Kamrowski; Ashwin Chandra; Tatjana Talamantes; Lewis R Baxter; Laszlo Prokai
Journal:  Int J Mol Sci       Date:  2013-11-26       Impact factor: 5.923

10.  Overcoming scientific and structural bottlenecks in antibacterial discovery and development.

Authors:  Anna Zorzet
Journal:  Ups J Med Sci       Date:  2014-03-19       Impact factor: 2.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.